Zentalis Pharmaceuticals Announces Board and Executive Changes
Ticker: ZNTL · Form: 8-K · Filed: Dec 15, 2025 · CIK: 1725160
Sentiment: neutral
Topics: board-changes, executive-compensation, governance
Related Tickers: ZNTL
TL;DR
Zentalis board shake-up and exec comp changes filed 12/15/25.
AI Summary
Zentalis Pharmaceuticals, Inc. announced on December 15, 2025, changes in its board of directors and executive compensation arrangements. Specifically, the company reported the departure of certain officers and directors, the election of new directors, and updates to compensatory arrangements for its officers.
Why It Matters
Changes in a company's board and executive compensation can signal shifts in strategy, governance, or financial outlook, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in board composition and executive compensation can indicate internal shifts that may affect company strategy and performance.
Key Players & Entities
- Zentalis Pharmaceuticals, Inc. (company) — Registrant
- December 15, 2025 (date) — Date of earliest event reported
FAQ
Who departed from Zentalis Pharmaceuticals' board or officer positions?
The filing indicates the departure of certain officers and directors, but does not name specific individuals in this 8-K filing.
Were any new directors elected to the Zentalis Pharmaceuticals board?
Yes, the filing reports the election of new directors to the Zentalis Pharmaceuticals board.
What specific changes were made to executive compensation arrangements?
The filing states that there were updates to compensatory arrangements of certain officers, but the specific details are not provided in this 8-K.
What is the filing date for this 8-K report?
The report was filed on December 15, 2025.
What is Zentalis Pharmaceuticals' Standard Industrial Classification (SIC) code?
Zentalis Pharmaceuticals' SIC code is 2834, for Pharmaceutical Preparations.
Filing Stats: 882 words · 4 min read · ~3 pages · Grade level 12.4 · Accepted 2025-12-15 17:01:42
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share ZNTL The Nasdaq Glo
- $1.33 — common stock from Matrix at a price of $1.33 per share, representing a discount from
- $1.40 — om the Company's closing share price of $1.40 on December 12, 2025 (the "Repurchase")
Filing Documents
- zntl-20251215.htm (8-K) — 31KB
- 0001725160-25-000164.txt ( ) — 167KB
- zntl-20251215.xsd (EX-101.SCH) — 2KB
- zntl-20251215_def.xml (EX-101.DEF) — 6KB
- zntl-20251215_lab.xml (EX-101.LAB) — 24KB
- zntl-20251215_pre.xml (EX-101.PRE) — 17KB
- zntl-20251215_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On December 15, 2025 (the "Effective Date"), the Company entered into a Stock Purchase Agreement (the "Agreement") with Matrix Capital Master Fund, LP ("Matrix"). Pursuant to the Agreement, the Company agreed to repurchase 7,500,000 shares of the Company's common stock from Matrix at a price of $1.33 per share, representing a discount from the Company's closing share price of $1.40 on December 12, 2025 (the "Repurchase"). The Repurchase closed on December 15, 2025. The Repurchase is being effected in connection with the plan by Matrix Capital Management Company L.P., the investment advisor to Matrix, to wind down its family of funds, previously announced in 2024. The Company does not expect the Repurchase to materially impact its projected cash runway into late 2027.
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K ("Form 8-K") contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation, statements regarding the impact of the Repurchase on the Company's expected cash runway into late 2027. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the important factors discussed in the sections entitled "Risk Factors" in our most recently filed periodic report on Form 10-K or 10-Q and subsequent filings with the U.S. Securities and Exchange Commission (SEC) and our other filings with the SEC. The forward-looking statements in this Form 8-K are based upon information available to the Company as of the date of this Form 8-K, and while the Company believes such information forms a reasonable basis for such statements, such information may be limited or incomplete, and the statements should not be read to indicate that the Company has conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. While the Company may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ZENTALIS PHARMACEUTICALS, INC. Date: December 15, 2025 By: /s/ Julie Eastland Julie Eastland President and Chief Executive Officer